Echocardiography results of protocol 2
| Protocol 2, day 2 . | Control . | Cfz . |
|---|---|---|
| . | n = 5 . | n = 6 . |
| HR | 651.46 ± 16.02 | 648.38 ± 23.15 |
| LVEDD, mm | 3.06 ± 0.07 | 3.28 ± 0.11 |
| LVESD, mm | 1.66 ± 0.06 | 1.97 ± 0.07* |
| LVPWd, mm | 0.75 ± 0.01 | 0.73 ± 0.01 |
| LVPWs, mm | 1.27 ± 0.01 | 1.24 ± 0.01 |
| FS, % | 45.67 ± 1.07 | 39.88 ± 0.20*** |
| r/h | 2.07 ± 0.06 | 2.21 ± 0.09 |
| Protocol 2, day 2 . | Control . | Cfz . |
|---|---|---|
| . | n = 5 . | n = 6 . |
| HR | 651.46 ± 16.02 | 648.38 ± 23.15 |
| LVEDD, mm | 3.06 ± 0.07 | 3.28 ± 0.11 |
| LVESD, mm | 1.66 ± 0.06 | 1.97 ± 0.07* |
| LVPWd, mm | 0.75 ± 0.01 | 0.73 ± 0.01 |
| LVPWs, mm | 1.27 ± 0.01 | 1.24 ± 0.01 |
| FS, % | 45.67 ± 1.07 | 39.88 ± 0.20*** |
| r/h | 2.07 ± 0.06 | 2.21 ± 0.09 |
Echocardiographic assessment of cardiac function in Cfz-treated mice indicated a moderate but significant LV dilation and FS% reduction vs control group at day 2 (*P < .05, **P < .01, ***P < .001).
HR, heart rate (beats/min); r/h: left ventricular radius to left ventricular posterior wall thickness ratio.